+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Drug Pipeline Report 2020 - Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

  • ID: 4849224
  • Drug Pipelines
  • October 2019
  • Region: Global
  • 40 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Destiny Pharma Plc
  • HyPharm GmbH
  • Naicons Srl
  • Sealife PHARMA GMBH
  • MORE
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Drug pipeline report- 2020 is an annual R&D review of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline candidates. The report presents the current status of all major Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapeutic compounds. Detailed insights into Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline development, current status, companies, drug profiles and Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections preclinical and clinical trials are included.

2020 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Market Insights
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections therapies, pipeline by phase and others are included.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drug Profiles
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Therapeutic Drug Candidates
Both active and inactive Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline drug candidates are included in the report

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Clinical Trials and Preclinical Studies
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Market Developments
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Companies in Active Development
The report analyzes Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline of the below companies-
Debiopharm International SA, Destiny Pharma Plc, HyPharm GmbH, Naicons Srl, Sealife PHARMA GMBH, Tetraphase Pharmaceuticals Inc

Report Coverage
- What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included
- Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others
- Companies
6 Companies investing in Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline from discovery stage to pre-registration phase are included
- Drug profiles
Over 10 details of each Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline candidate are included
- Company Profiles
Business overview and contact details of all companies operating in the industry are provided
- Market Developments
News, Developments and other recent industry developments are included
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Destiny Pharma Plc
  • HyPharm GmbH
  • Naicons Srl
  • Sealife PHARMA GMBH
  • MORE
1. Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Market Insights, 2020
1.1 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Disease Overview
1.2 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Drug Pipeline Snapshot, 2020
1.2.1 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs by Phase
1.2.2 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs by Company
1.2.3 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs by Mechanism of Action
1.2.4 Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs by Route of Administration

2. Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Company wise Pipeline Details
Debiopharm International SA Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Destiny Pharma Plc Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
HyPharm GmbH Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Naicons Srl Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Sealife PHARMA GMBH Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
Tetraphase Pharmaceuticals Inc Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline Drugs
  • Company Profile
  • Drug Candidate Details
3. Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Drug Pipeline Profiles
3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections Pipeline News and Developments

5. Appendix
5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Debiopharm International SA
  • Destiny Pharma Plc
  • HyPharm GmbH
  • Naicons Srl
  • Sealife PHARMA GMBH
  • Tetraphase Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll